Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone

J Clin Oncol. 2010 Dec 1;28(34):e704-8. doi: 10.1200/JCO.2010.30.0038. Epub 2010 Sep 7.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Cytarabine / administration & dosage
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Dexamethasone / administration & dosage
  • Filgrastim
  • Gemcitabine
  • Granulocyte Colony-Stimulating Factor / administration & dosage
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • Humans
  • Lenalidomide
  • Lymphoma, Large-Cell, Immunoblastic / drug therapy*
  • Lymphoma, Large-Cell, Immunoblastic / pathology
  • Lymphoma, Large-Cell, Immunoblastic / virology
  • Male
  • Neoplasm Staging
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Polyethylene Glycols
  • Pyrazines / therapeutic use*
  • Recombinant Proteins
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use
  • Young Adult

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Organoplatinum Compounds
  • Pyrazines
  • Recombinant Proteins
  • Cytarabine
  • Oxaliplatin
  • Deoxycytidine
  • Granulocyte Colony-Stimulating Factor
  • pegfilgrastim
  • Polyethylene Glycols
  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • Lenalidomide
  • Filgrastim
  • Gemcitabine